Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 250 entries
View as:

Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL

Phase: N/A Priority: Normal
NCT ID: NCT06658925 Org: User:
Start: 11/01/24 End: 08/31/27 Due: 08/31/28

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT05925504 Org: User:
Start: 07/01/23 End: 09/30/26 Due: 09/30/27

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04322292 Org: User:
Start: 09/12/19 End: 11/30/21 Due: 11/30/22

Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT06658938 Org: User:
Start: 11/01/24 End: 10/01/26 Due: 10/01/27

Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06643195 Org: User:
Start: 01/01/25 End: 09/30/27 Due: 09/30/28

Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

Phase: N/A Priority: Normal
NCT ID: NCT06529250 Org: User:
Start: 08/13/24 End: 09/01/28 Due: 09/01/29

A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT06770504 Org: User:
Start: 01/16/25 End: 12/30/26 Due: 12/30/27

CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Phase: N/A Priority: Normal
NCT ID: NCT06231368 Org: User:
Start: 02/04/24 End: 08/31/25 Due: 08/31/26

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT06168851 Org: User:
Start: 12/28/23 End: 12/31/25 Due: 12/31/26

Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06224257 Org: User:
Start: 12/03/23 End: 10/31/25 Due: 10/31/26

A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT05904067 Org: User:
Start: 06/10/23 End: 01/01/25 Due: 01/01/26

Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT07010237 Org: User:
Start: 02/01/25 End: 07/01/29 Due: 07/01/30

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT06094881 Org: User:
Start: 12/01/23 End: 11/30/26 Due: 11/30/27

A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP

Phase: N/A Priority: Normal
NCT ID: NCT06838949 Org: User:
Start: 03/03/25 End: 12/31/27 Due: 12/31/28

Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT05727917 Org: User:
Start: 01/01/23 End: 10/31/24 Due: 10/31/25

CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT06622694 Org: User:
Start: 10/07/24 End: 12/31/26 Due: 12/31/27

Avatrombopag for Chemotherapy-induced Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05218226 Org: User:
Start: 02/10/22 End: 12/31/25 Due: 12/31/26

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05846750 Org: User:
Start: 11/01/22 End: 05/31/28 Due: 05/31/29

Safety and Efficacy Study of NGGT003 in Hemophilia A Patients

Phase: N/A Priority: Normal
NCT ID: NCT06238908 Org: User:
Start: 01/17/24 End: 01/31/30 Due: 01/31/31

A Study of CT0596 in Plasma Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06988059 Org: User:
Start: 05/26/25 End: 12/31/27 Due: 12/31/28

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT06799611 Org: User:
Start: 03/03/25 End: 01/31/27 Due: 01/31/28

Eltrombopag for Chemotherapy-induced Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT04600960 Org: User:
Start: 12/31/20 End: 12/31/25 Due: 12/31/26

Gene Therapy for Chinese Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT04728841 Org: User:
Start: 03/04/21 End: 07/31/28 Due: 07/31/29

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04423367 Org: User:
Start: 09/13/20 End: 09/30/24 Due: 09/30/25

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

Phase: N/A Priority: Normal
NCT ID: NCT06208137 Org: User:
Start: 02/29/24 End: 04/01/28 Due: 04/01/29